Purpose of review-The purpose of the present review is to describe new, innovative strategies of diagnosing and treating specific human cancers using a cadre of radiolabeled regulatory peptides.
Introduction
Molecular imaging is defined as the visualization, characterization, and measurement of biological processes at the molecular and cellular levels in humans and other living systems. Molecular imaging is a noninvasive procedure that involves clinical in-vivo administration of a biologically active, receptor-specific, targeting vector (i.e., peptides, small proteins, antibody fragments, or intact antibodies) conjugated to a radioligand, nanoparticle, and/or fluorescent/ magnetic resonance imaging (MRI) probe followed by acquisition and quantification of signal by positron emission tomography (PET), single photon emission computed tomography (SPECT), MRI, fluorescence imaging, or ultrasound [1] .
Radiolabeled, regulatory peptides continue to hold promise for early diagnosis or treatment of human disease [2 • ]. The interest in radiolabeled peptides for molecular imaging or peptide receptor-targeted radionuclide therapy (PRTRT) stems from their ability to be easily produced, rapid clearance from whole blood, ease of penetration into the tumor vascular endothelium, relatively low immunogenicity, and rapid excretion from the human body [1] . Furthermore, radiolabeled regulatory peptides can be chemically tuned to target cell-surface receptors that tend to be expressed in very high numbers on human cancer cells, offering the advantage of identifying and treating diseased human tissue with minimal collateral damage to neighboring, normal tissues [2 • ].
Peptide-based targeting vectors for molecular imaging or PRTRT (Fig. 1 ) are composed of a targeting vector (regulatory peptide), pharmacokinetic modifier (hydrophilic aliphatic or amino acid tethering molecule), bifunctional chelating agent (BFCA, a complexing agent capable of producing a kinetically-inert, in-vivo radiometal/ligand complex while linking it to the regulatory peptide), and radiometal [γ-emitting or positron-emitting (γ or β + , Table 1 ) diagnostic or β-emitting or α-emitting (β − or α, Table 2 ) therapeutic radionuclide] [3] .
Herein we report recent investigations that describe advances and new targeting strategies using radiolabeled regulatory peptides for molecular imaging or PRTRT of specific human disease. Specifically, we attempt to highlight somatostatin, gastrin-releasing peptide, and melanocortin receptor-targeting peptides, and recent advances in radiolabeled, multimeric/multivalent regulatory peptides for targeting multiple cell-surface receptor subtypes.
Somatostatin receptor-targeting peptides
To date, radiolabeled analogues of somatostatin (SST) have been the gold standard for peptidereceptor imaging and therapeutic agents. For example, the clinical successes of octreoscan for visualizing primary and meta-static SST receptor-positive tumors have paved the way for exploration and radiolabeling of other biologically active regulatory peptides described herein. SST, a peptide hormone expressed in the central and peripheral nervous systems, exists naturally in two forms: SST-14 and SST-28. SST-14 and SST-28 have a cyclic structure due to the presence of a single disulfide bond. Five known G protein-coupled receptor SST subtypes exist, SSTR1-5. SSTR1-5 are expressed in very high numbers on tumors of neuroendocrine origin, with SSTR2 being the most prolific. Therefore, radiolabeled agents based upon SSTRtargeting peptides are viable candidates for site-directed molecular imaging or PRTRT of neuroendocrine receptor-expressing tumors [3] . (Fig. 2 ) that has been radiolabeled with Cu-64. This new conjugate is a potentially useful SSTR antagonist for PET imaging of SSTR-positive tumors. In this study, they determined that [ 64 Cu-CB-TE2A-sst 2 -ANT] showed higher tumorto-blood and tumor-to-muscle ratios as compared with [ 64 Cu-CB-TE2A-Y3-TATE], an SSTR2-positive agonist. MicroPET/CT imaging of male Lewis rats bearing AR42J tumors showed high-quality diagnostic images with excellent tumor-to-background contrast at 4 h postintravenous injection [7 • ]. In addition, Cescato et al. [8] recently reported a series of new DOTA-conjugated SSTR2 antagonists that exhibit antagonist-like behavior in vitro. Pertaining to this original work, Reubi and Maecke [2 • ] have recently indicated that a clinical trial using a radiolabeled DOTA-conjugated SSTR2 antagonist is currently underway.
Gastrin-releasing peptide receptors
Gastrin-releasing peptide (GRP) receptors are present in high concentrations in human cancers such as prostate, breast, pancreatic, and small cell lung carcinoma [9 •• ] . Mammalian bombesin receptors are G protein-coupled, seven-transmembrane receptors having the capacity to be endocytosed upon binding by an effective agonist ligand. There are three known mammalian bombesin receptor subtypes: BB1 (neuromedin B receptors, NMBR), BB2 (gastrin-releasing peptide receptors, GRPRs), and BB3 (BRS-3) [10] . To date, design and development of radiolabeled agents for the mammalian bombesin receptors have focused on the highly prolific BB2 receptor subtype targeted by bombesin peptide (BBN) or BBN-like analogues. BBN is the 14 amino acid amphibian peptide analogue of the 27 amino acid mammalian regulatory peptide GRP. BBN and GRP share a homologous 7 amino acid amidated C-terminus, [-WAVGHLM-NH 2 ], which is essential for high-affinity receptor binding to GRPR. The ability of GRPR agonists to be rapidly internalized coupled with a high incidence of GRPR expression on various neoplasias has been a driving force for design and development of new diagnostic and therapeutic agents targeting GRPR-positive tumors [11 • ].
[BBN (7) (8) (9) (10) (11) (12) (13) (14) Fig. 3) with Cu-64 that has resulted in tumor uptake of 3.59 ± 0.70 % ID/g at 1 h postintravenous injection in PC-3 tumor-bearing severe combined immunodeficient (SCID) mice and 2.27 ± 0.08 %ID/g at 1 h postintravenous injection in T-47D tumor-bearing SCID mice. High-quality, high-contrast microPET images were obtained in both mouse models. Another successful [BBN (7) (8) (9) (10) (11) (12) (13) (14) 14 have been replaced by Cha and Nle, respectively. This peptide modification has been reported to increase metabolic stability in human plasma and PC-3 cells. The use of the polar glycated linker had beneficial pharmacokinetic effects by significantly reducing liver accumulation (0.6 vs. 2.4 %ID/g, 1.5 h postintravenous injection), increasing PC-3 tumor uptake (3.6 %ID/g, 1.5 h), and improving tumor-to-background ratios in vivo (17-fold at 1.5 h postintravenous injection). 4) and radiosynthesis of corresponding In-111, Y-86, and Ga-68 conjugates. CHX-A″ is a poly (aminocarboxylate) chelating ligand for lanthanide or lanthanide-like radioelements based upon DTPA (diethylaminetriaminepentaacetic acid). CHX-A″ can be radiolabled using milder conditions and under shorter incubation periods as compared with DOTA. In this study, the new conjugates displayed high tumor uptake and retention in B16/F1 melanoma-bearing C57 mice with 4.17 ± 0.94 (In-111), 4.68 ± 1.02 (Y-86), and 2.68 ± 0.69 (Ga-68) %ID/g present in tumor at 4 h postintravenous injection, respectively. While high-resolution, high-contrast microPET images were obtained in rodent models, tumor accumulation was moderated by lowspecific activity radiolabeled peptide.
New and improved radiolabeling and targeting strategies for the MC1R on melanoma are clearly warranted. Alternative to CCSMH-targeting vector, Miao et al. [19] and Guo et al. [20] have recently reported lactam bridge-cyclized α-MSH peptide analogues for diagnostic molecular imaging of melanoma. In these studies, they reported high tumor uptake and retention of radioactivity in either B16/F1 or B16/F10 melanoma-bearing C57 mice. Although high-resolution, high-contrast microPET images of primary and metastatic disease were obtained for the new conjugates, the results do not appear to be altogether superior to the metalcyclized [Re(Arg 11 ) CCMSH] regulatory peptide analogues. Additionally, Raposinho et al. [21, 22] have used a pyrazolyl ligand framework to stabilize the low-valent, fac-[ 99m Tc (CO) 3 ] + metal center for potential SPECT imaging of MC1R-positive melanoma tumors. Lastly, Bapst et al. [23] have evaluated glycosylated DOTA-α-MSH analogues radiolabeled with In-111. They have determined that high-tumor uptake and low-renal retention of conjugate in B16/F1 melanoma-bearing B6D2F1 female mice clearly brings impetus for design and development of new radiolabeled regulatory peptides for targeted diagnosis and PRTRT of MC1R-positive human tumors.
Arginine-glycine-aspartic acid multimeric receptor-targeting peptides
Angiogenesis is the physiological process for growth of new blood vessels from existing ones and is a regulatory mechanism for transition of tumor tissue from a dormant to a malignant or metastatic state [24] . Integrins are cell-surface transmembrane glycoproteins existing as αβ heterodimers. α v β 3 and α v β 5 -integrin subtypes are expressed on the endothelial cells of tumor neovasculature during angiogenesis and form the basis of investigations for molecular imaging and PRTRT of angiogenesis and tumor formation in vivo. The α v β 3 -integrin is known to be expressed in very high numbers in many tumor cell types, including lung carcinomas, osteosarcomas, breast cancer, and glioblastomas [25] . Radiolabeled peptides containing the amino acid sequence [Arg-Gly-Asp] (RGD) are nonregulatory peptides that have been used extensively to target α v β 3 receptors upregulated on tumor cells and neovasculature, therefore providing a molecular vehicle for early detection of rapidly growing tumors and metastatic disease [25] .
The clinical utility of monomeric radiolabeled peptides can be limited by a number of factors, including receptor density, binding affinity, and pharmacokinetics. For example, high-quality, high tumor-to-background PET or SPECT images require a high degree of receptor expression on tumor cells as compared with normal, collateral tissue. 
Conclusion
For more than a decade, the field of nuclear medicine has been investigating the usage of radiolabeled regulatory peptides for molecular targeting of receptors highly expressed on specific human tumors. The clinical successes of octreoscan have paved the way for exploration and radiolabeling of other biologically active regulatory peptides and some of them have been described herein. Other cancer types that express regulatory peptide receptors in very high numbers include neuropeptide-Y (NPY) receptors in breast tumors, glioblastomas, and sarcomas; glucagon-like-peptide-1 (GLP-1) receptors in insulinomas; cholecystokinin-2 (CCK2) receptors in medullary thyroid cancers; and neurotensin receptors in pancreatic cancers [2 • ]. Continued design and development of multi-meric or multivalent peptides capable of targeting multiple receptor subtypes highly expressed on human cancers could do much to improve image resolution and contrast, all but eliminating the high false-positive rates and nontarget uptake that oftentimes limits some of the clinically approved radiopharmaceuticals from widespread usage for diagnosis of malignant tissues. Furthermore, the ability to target specific receptors highly expressed on the surfaces of human cancer cells creates the opportunity to use PRTRT as a highly selective treatment strategy for tumor targeting or as a mechanism for this treatment strategy to complement traditional, clinically useful chemotherapeutic regimens of treatment. A representative outline of a peptide-based targeting vector for molecular imaging or therapy of specific human cancers 
